Trial Profile

A phase 1 trial of SIL-204

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SIL 204 (Primary)
Indications Pancreatic cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

25 Mar 2025 New trial record
24 Mar 2025 According to a Silexion Therapeutics, company announced that it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the companys management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th to 29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com